Charles Buck has been the Director of Operations for the Bindley Bioscience Center (BBC) at Purdue University’s Discovery Park since December, 2004. He coordinates multidisciplinary scientific research efforts as well as overseeing the day-to-day activities of the BBC. His responsibilities include organizing research grant initiatives, managing large scale research projects, directing research services, quality assurance and compliance, and recruitment and management of Bindley research staff. Engagement with corporate partners and commercialization of Purdue technology are key Discovery Park metrics and another focus of activity for Charles.
Dr. Buck was previously Chief Scientific Officer at Oridis Biomed in Graz, Austria, a company that he co-founded in 2001. Dr. Buck successfully developed partnerships, generated capital funding, managed the research activity, and developed the patent portfolio of the company. He earned his Ph.D. in Molecular Neurobiology at Cornell University Graduate School of Medical Sciences in 1988. Prior to starting Oridis, he held faculty positions at Emory University School of Medicine, the Medical University of South Carolina (MUSC) and the University of Utah School of Medicine.
His research expertise is in the molecular biology of vertebrate nervous system development and response to injury as well as in human liver diseases and cancer. With broad experience with high throughput gene and protein expression analysis, he has received research project funding from the NIH, the American Paralysis Association, the Austrian Genome Project, and the European Commission Framework Programme 6.
How did you first hear about nanoHUB?
What is the primary purpose of your visit to nanoHUB?